Search

Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromid

Commercial launch of ECCLOCK® in Japan currently underway by Development Partner, Kaken Pharmaceutical

111921 Brickell Biotech Announces Public
.
Download • 91KB